Processa Pharmaceuticals' Promising Phase 2 Results Boost Stock

Processa Pharmaceuticals shares are trading higher after the company announced positive clinical update from its Phase 2 study in metastatic breast cancer, highlighting increased cancer-killing metabolite exposure while maintaining safety.